A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer
about
DNA repair targeted therapy: The past or future of cancer treatment?Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian CancerThe role of PARP in DNA repair and its therapeutic exploitationUse of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinicPredictors and Modulators of Synthetic Lethality: An Update on PARP Inhibitors and Personalized MedicineNuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancerA phenotypic mouse model of basaloid breast tumorsA Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage ResponsPhase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses.Dynamic In Vivo Profiling of DNA Damage and Repair after Radiotherapy Using Canine Patients as a Model.Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes.Assessing the function of homologous recombination DNA repair in malignant pleural effusion (MPE) samples.Functional characterization of breast cancer using pathway profilesPARP inhibitors in BRCA gene-mutated ovarian cancer and beyond.BRCA1 pathway function in basal-like breast cancer cells.An ex vivo assay of XRT-induced Rad51 foci formation predicts response to PARP-inhibition in ovarian cancerSubtyping of triple-negative breast cancer: implications for therapyPersonalizing health care: feasibility and future implications.Rad51 inhibition is an effective means of targeting DNA repair in glioma models and CD133+ tumor-derived cellsSynthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations.Mutation at intronic repeats of the ataxia-telangiectasia mutated (ATM) gene and ATM protein loss in primary gastric cancer with microsatellite instabilityDNA damage response and DNA repair - dog as a model?Predicting early brain metastases based on clinicopathological factors and gene expression analysis in advanced HER2-positive breast cancer patients.The ups and downs of DNA repair biomarkers for PARP inhibitor therapiesThe potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy.DNA repair: from genome maintenance to biomarker and therapeutic target.Development of a multiparameter flow cytometric assay as a potential biomarker for homologous recombination deficiency in women with high-grade serous ovarian cancer.Whole genomes redefine the mutational landscape of pancreatic cancer.Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival.DNA Damage Response Assessments in Human Tumor Samples Provide Functional Biomarkers of Radiosensitivity.Overexpression of Cell Cycle Progression Inhibitor Geminin is Associated with Tumor Stem-Like Phenotype of Triple-Negative Breast CancerCross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib.Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatmentActivation of homologous recombination DNA repair in human skin fibroblasts continuously exposed to X-ray radiationA Case of Metaplastic Breast Cancer with Prolonged Response to Single Agent Liposomal Doxorubicin.Predictive significance of DNA damage and repair biomarkers in triple-negative breast cancer patients treated with neoadjuvant chemotherapy: An exploratory analysis.A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: do we still need it?Proteomics of genetically engineered mouse mammary tumors identifies fatty acid metabolism members as potential predictive markers for cisplatin resistance.Therapeutic applications of PARP inhibitors: anticancer therapy and beyondmTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer.
P2860
Q26768679-1446A4D1-E67E-43EE-A503-FCE9185BC968Q26783551-7D7C3670-DF2B-4236-A730-BBACA450937FQ27002399-440531F1-E29E-445B-9E86-BDB112ACCFB5Q28071541-006E59B6-785B-4DE5-BC75-DA624407440FQ28072204-0364F7F6-2FC4-4773-AFCC-57A4BA233718Q28247712-545669CF-C81D-404A-BE50-E7EA1894EEF5Q28480588-E5891C77-436B-4E67-ACC8-536DE3DF4EDCQ30253017-AA66C043-8D1B-479D-85C3-4BCC29A0B461Q33415400-C1BF052F-77EE-4895-89C6-3D1BECF2F0C8Q33838607-F69B0D66-67F2-4CA7-92C1-4D60AFFB3FDAQ33874621-0041A421-03A0-4DC8-9FF8-37622A7B34C4Q33877435-608EB35A-8978-4802-A379-845DD292142CQ33962784-8B9B08E7-8BF2-4C42-888D-4AB52AEB3935Q34215904-AC47AAEA-AFC9-427F-B8FF-495319E1C5F9Q34297981-C21B67D5-A062-4123-975E-FA5E32D74C24Q34458291-E00D6753-6002-4B75-A083-98CFA4E24A01Q34734477-00170A49-16CF-4C64-9C3A-EA1A66FFCAA5Q34938911-2C4FCD3F-77C4-49E4-8B15-66A85A630D36Q34977354-7AC01E02-F953-44D2-AFA5-5E13C45E7ADBQ35051154-79E04FC8-B289-4AAD-B5AA-65EA3C591E5DQ35064299-553FFA9A-A649-4617-99C9-AC012321D2F6Q35123713-01EEE5AB-3662-4987-9581-AEA06FC7F9BCQ35159916-D2A5EC66-0E93-4DC2-81D8-E4892E16AB47Q35232277-77EE12CC-318E-4E45-882B-E82CA8A1E347Q35534509-E638E8B0-162C-4882-8E67-EB2A044E5CB7Q35555880-9ED00795-AF1C-4837-8ADE-C5BBC7A8E70AQ35869645-A507586E-2DA7-43BB-94CB-E62F17CBDDA1Q35911034-CC78E02F-B613-4ACE-A558-11972493B0AFQ36070080-37F23FE6-5DD1-4FBA-B441-D071E1D205C3Q36073749-64D63C99-3202-4A54-9A69-DB356CF92A0CQ36092011-55E99678-CAF5-462F-920E-A31849C9885DQ36195450-CBD1A445-8C59-46C7-8D56-6A431D1FDF27Q36392155-6F86C459-6AD3-45EB-9A49-F860EE7DECECQ36413634-08101028-DE65-45B5-978F-4BE414A68156Q36576414-C9AA2507-C1BD-47CA-83DE-39B9A6556B29Q36619000-377A397C-D41D-4F49-8A54-2C6FAF675BE6Q36689744-55943E9D-CA44-4FF6-ABBC-C45DBD358C7EQ36832502-C294B680-E696-4EE9-A087-FE59B79ABEA9Q36853236-6F96E3BD-FF9B-4479-94D0-1FE10587E064Q36874139-C99C1E0D-96E8-460A-B274-DED9C327D9C8
P2860
A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
A marker of homologous recombi ...... erapy in primary breast cancer
@ast
A marker of homologous recombi ...... erapy in primary breast cancer
@en
type
label
A marker of homologous recombi ...... erapy in primary breast cancer
@ast
A marker of homologous recombi ...... erapy in primary breast cancer
@en
prefLabel
A marker of homologous recombi ...... erapy in primary breast cancer
@ast
A marker of homologous recombi ...... erapy in primary breast cancer
@en
P2093
P2860
P50
P1476
A marker of homologous recombi ...... erapy in primary breast cancer
@en
P2093
Afshan McCarthy
Ian E Smith
Janine Salter
Kay Savage
Margaret Hills
Marina Parton
Monika Graeser
Nicholas C Turner
Nicholas Orr
P2860
P304
P356
10.1158/1078-0432.CCR-10-1027
P407
P577
2010-08-27T00:00:00Z